Chrysalis Ventures

Total investments

77

Average round size

7M

Portfolio companies

43

Rounds per year

2.66

Lead investments

17

Follow on index

0.44

Exits

20

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyInternetSoftwareAnalyticsInformation TechnologyInformation ServicesHealth CareHealth DiagnosticsMedical DeviceMedical

Summary

In 1993 was created Chrysalis Ventures, which is appeared as VC. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Louisville.

Among the most popular portfolio startups of the fund, we may highlight Intechra Holdings, Laboratory Partners, AlayaCare. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

We also calculated 3 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Chrysalis Ventures, startups are often financed by LiveOak Equity Partners, Claritas Capital, Arboretum Ventures. The meaningful sponsors for the fund in investment in the same round are Arboretum Ventures, Richland Ventures, Claritas Capital. In the next rounds fund is usually obtained by Arboretum Ventures, Richland Ventures, Adams Street Partners.

The fund is generally included in 2-6 deals every year. Opposing the other organizations, this Chrysalis Ventures works on 10 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2014. The top activity for fund was in 2009. Despite it in 2019 the fund had an activity. When the investment is from Chrysalis Ventures the average startup value is 50-100 millions dollars. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations. Deals in the range of 5 - 10 millions dollars are the general things for fund.

Show more

Investments analytics

Analytics

Total investments
77
Lead investments
17
Exits
20
Rounds per year
2.66
Follow on index
0.44
Investments by industry
  • Health Care (34)
  • Software (22)
  • Medical (15)
  • Internet (14)
  • Information Technology (9)
  • Show 55 more
Investments by region
  • United States (74)
  • Canada (2)
  • United Kingdom (1)
Peak activity year
2009

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
18
Avg. valuation at time of investment
10M
Group Appearance index
0.79
Avg. company exit year
13
Avg. multiplicator
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
BehaVR 13 Dec 2022 Health Care, Virtual Reality, Therapeutics Early Stage Venture 13M United States, Kentucky, Elizabethtown
My Health Direct 15 Dec 2009 Health Care, Hospital, Medical Early Stage Venture 4M United States, Wisconsin
Village Baby 19 Oct 2021 E-Commerce, Information Technology, Consumer, Women's, Child Care Seed 696K Gangwon-do, South Korea, South Korea

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.